Brind.

GeoVax is advancing Gedeptin into a combination trial, and Kelly McKee serves as the Chief Medical Officer at the company.

1 report, 1 independent Updated Jul 24
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

GeoVax is advancing Gedeptin into a combination trial, and Kelly McKee serves as the Chief Medical Officer at the company.

Who's involved

What this event is mainly about
GeoVaxAdvance

Keep exploring

The entities involved

  • GeoVax

    biotechnology company

    Nothing else this week.

  • Advance

    company in Tokyo, Japan

    Nothing else this week.

Coverage

Newest first; wire copies grouped
  • NewMediaWireGeoVax to Advance Gedeptin(R) Into First-Line Therapy Neoadjuvant Combination Trial Following Landmark KEYNOTE-689 Results Revised Phase 2 Strategy Targets Event-Free Survival in Primary Head and Nec